Clinical Trials Directory

Trials / Sponsors / Aprea Therapeutics

Aprea Therapeutics

Industry · 12 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingStudy of APR-1051 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 12024-06-13
Active Not RecruitingStudy Of ATRN-119 In Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1 / Phase 22023-01-09
TerminatedAPR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
MDS, Myelodysplastic Syndromes
Phase 12021-09-20
TerminatedAPR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphom
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase 1 / Phase 22021-03-02
CompletedPhase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer
Phase 1 / Phase 22020-06-25
CompletedAPR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Myeloid Malignancy
Phase 12019-12-13
CompletedAPR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase 22019-09-16
CompletedAPR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
MDS
Phase 32019-01-11
TerminatedA Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Melanoma
Phase 1 / Phase 22018-01-18
Completedp53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
High-grade Serous Ovarian Cancer
Phase 22017-07-31
Completedp53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carbo
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Phase 1 / Phase 22014-03-01
CompletedSafety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Hematologic Neoplasms, Prostatic Neoplasms
Phase 12009-05-01